News >

Sacituzumab Govitecan Shows Early Promise in Urothelial Carcinoma

Brandon Scalea
Published: Monday, Mar 04, 2019

Scott Tagawa, MD

Scott Tagawa, MD

Sacituzumab govitecan seemed to effectively achieve its goal of delivering the potent toxin SN-38 to tumor cells and sparing normal cells in patients with advanced urothelial carcinoma, said Scott T. Tagawa, MD.

In results of a phase I/II study (NCT01631552) presented at the 2019 Genitourinary Cancers Symposium, the antibody-drug conjugate (ADC) demonstrated clinical activity in patients with advanced urothelial carcinoma, including those who were previously treated with checkpoint inhibition and those with visceral disease.

In 45 patients, the objective response rate (ORR) was 31.1% (95% CI, 18.2-46.6), including a complete response rate of 4% and a partial response rate of 27%. Median progression-free survival (PFS) and overall survival (OS) were 7.3 months (95% CI, 5.0-10.7) and 16.3 months (95% CI, 9.0-31.0), respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x